Arlington Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-220
Closed -$7K 368
2022
Q2
$7K Buy
+220
New +$7.69K ﹤0.01% 399

Other funds holding ARKG

Arlington Partners's ARKG Position: Q3 2022 in Review

Arlington Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 220 shares — an estimated $7K sold.

Arlington Partners first reported a position in ARKG in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

  • Arlington Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
  • Arlington Partners sold 220 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $7K.
  • Arlington Partners first reported a position in ARK Genomic Revolution ETF in Q2 2022 and held it in 1 quarter.
  • Arlington Partners's ARK Genomic Revolution ETF position peaked at $7K in Q2 2022.
  • 311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on Arlington Partners's 13F filing for Q3 2022, filed 28 Oct 2022.